TheraRadar
Data updated: May 26, 2026

OTOVEL (ciprofloxacin hydrochloride)

Ophthalmology Approved 2016-04-29

OTOVEL is indicated for the treatment of Bacterial Conjunctivitis.

Source: FDA Label • LAB SALVAT
1
Indication
--
Phase 3 Trials
10
Years on Market

Details

Status
Prescription
First Approved
2016-04-29
Patent Cliff
2030

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
OTIC
Dosage Forms
SOLUTION/DROPS

OTOVEL Approval History

2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2016 to 2016
Apr 2016 ORIGINAL
Update · Type 5 - New Formulation or New Manufacturer

What OTOVEL Treats

1 indications

OTOVEL is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Bacterial Conjunctivitis
Source: FDA Label

OTOVEL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 4 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to OTOVEL

3 of 7

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZASITE
AZITHROMYCIN
1 shared
THEA PHARMA
Shared indications:
Bacterial Conjunctivitis
BESIVANCE
BESIFLOXACIN HYDROCHLORIDE
1 shared
BAUSCH AND LOMB
Shared indications:
Bacterial Conjunctivitis
CETRAXAL
CIPROFLOXACIN HYDROCHLORIDE
1 shared
LAB SALVAT
Shared indications:
Bacterial Conjunctivitis
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT00596453 results posted NA_00010549 Ph 4 terminated Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OTOVEL FDA Label Details

Indications & Usage

FDA Label (PDF)

OTOVEL is indicated for the treatment of Bacterial Conjunctivitis.

View full patent landscape →
1 OB patents · 1 families · 26 international docs across 16 countries

OTOVEL Patents & Exclusivity

Latest Patent: Mar 2030

Patents (1 active)

US8932610 Expires Mar 24, 2030
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for OTOVEL

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2030
  • 1 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • 7 similar drugs
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.